IMR Press / EJGO / Volume 39 / Issue 6 / DOI: 10.12892/ejgo4419.2018

European Journal of Gynaecological Oncology (EJGO) is published by IMR Press from Volume 40 Issue 1 (2019). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on as a courtesy and upon agreement with S.O.G.

Original Research
The TP53 - R72P (rs1042522) polymorphism and risk factors in breast cancer patients
Show Less
1 Laboratory of Molecular and Proteomic Gynecology, Gynecology Department – Federal University of São Paulo – Pedro de Toledo Street, São Paulo
2 Laboratory of Molecular and Structural Gynecology, Gynecology Department, University of São Paulo Faculty of Medicine – Dr. Arnaldo Avenue, São Paulo
3 Federal University of Pará – UFPA, Belém
4 Medicine Department of Federal University of Rondônia, Campus UNIR, Porto Velho, Brazil
Eur. J. Gynaecol. Oncol. 2018, 39(6), 963–972;
Published: 10 December 2018

The authors aimed to assess the incidence of TP53-R72P polymorphism correlating with risk factors and clinical-pathological features in breast cancer (BC). Genotypic distribution was higher for Arg/Pro (43.52%) comparing with Arg/Arg (38.36%) and Pro/Pro (18.12%), and the allele frequency was significantly higher for Arg (0.62%) in BC patients. Risk-factors such as age, menarche, pregnancy, hormonal therapy, ethnicity, and origin region showed relevance in case-control comparisons. Genotype distribution showed a high frequency of ER-positive and PR-positive in BC. HER-2 negative (87.8%) was significantly more frequently than positive, and the genotype classification was 40.5% Arg/Arg and 46.4% Arg/Pro. Almost all patients presented invasive ductal carcinoma (IDC) and underwent surgical treatment without neoadjuvant chemotherapy. TP53 - R72P polymorphism seems to be associated with some risk factors related to reproductive life, hormonal treatments, ethnicity, and lifestyle. Genetic variation between Arg and Pro alleles seems not to be directly correlated with BC development.
Breast Cancer
Genetic polymorphism
p53 protein
Back to top